Good morning, and happy Friday. This is Jonathan Wosen, West Coast biotech and life sciences reporter, filling in for Ed Silverman while he’s away from the Pharmalot campus. As you may know from my past entries, I’m no coffee drinker, but here are some newsy items to help wake you up and kick-start your weekend. …
The FDA has approved a cutting-edge treatment for a rare soft tissue cancer, STAT tells us. The therapy equips T cells, an important class of immune cell, to target synovial sarcomas, cancers that can form in muscles and ligaments. The drug is the first approved product by Adaptimmune, a biotech with operations split between Philadelphia and Oxford in the U.K.
Eli Lilly’s CEO says a shortage of its weight loss drug will end soon, Bloomberg notes. CEO David Ricks expects Zepbound to come off the FDA’s shortage list in the coming days. That announcement has already led to a sharp drop in share price for Hims & Hers Health, a telehealth company that sells a compounded or copycat version of a different weight loss drug, Wegovy.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect